Abstract
Hypertension is prevalent in over 25% of populations in developed countries, and poses an increasing economic burden on health resources. Therefore it is predicted that future medical treatment of hypertension will be increasingly affected by cost considerations. Several classes of antihypertensive drugs are used as first-line agents for the treatment of hypertension, but the economic impact of using these agents in different countries remains to be addressed. In this study, we compared health costs associated with treatment of hypertension using the calcium channel blocker amlodipine and the angiotensin-converting enzyme inhibitor enalapril in the US and Japan. Pharmaceutical costs and hospitalization costs were analyzed from established databases. The data for the prevalence of myocardial infarction and stroke were derived from the Framingham study and the Hisayama study. Analysis of the economic impacts using relative risk differences between the calcium channel blocker and angiotensin-converting enzyme inhibitor together with regional hospitalization costs resulted in an apparent 11.2 billion yen health cost reduction in favor of the calcium channel blocker in the case of Japan, in contrast to an apparent 5.7 billion yen reduction in favor of the angiotensin-converting enzyme inhibitor in the case of the US. The trends in Japan for 2000 and 2004 were similar. These results suggest that there are regional differences in the health costs associated with different classes of hypertensive agents, which could affect national policies on the choice of antihypertensive drugs. It is predicted that future treatment of hypertension will be increasingly tailored to the epidemiologic profiles and medical costs of individual communities.
Similar content being viewed by others
Article PDF
References
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J : Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–223.
Murray C, Lopez A : The Global Burden of Disease. Cambridge, Harvard University Press, 1996.
WHO: World Health Report 2002; Reducing Risk, Promoting Healthy Life. Geneva, World Health Organization, 2002.
Ishizaka N, Ishizaka Y, Toda E, Hashimoto H, Nagai R, Yamakado M : Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy Japanese individuals. Hypertens Res 2005; 28: 27–34.
Whitworth JA : 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.
Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
Japanese Society of Hypertension Guidelines Subcommittee : Guidelines for the Management of Hypertension (JSH 2000). Tokyo, Japanese Society of Hypertension, 2000.
Japanese Society of Hypertension Guidelines Subcommittee : Guidelines for the Management of Hypertension (JSH 2004). Tokyo, Japanese Society of Hypertension, 2004.
Sarti C, Rastenyte D, Cepaitis Z, Tuomilehto J : International trends in mortality from stroke, 1968 to 1994. Stroke 2000; 31: 1588–1601.
Shimamoto T, Komachi Y, Inada H, et al: Trends for coronary heart disease and stroke and their risk factors in Japan. Circulation 1989; 79: 503–515.
Saito I, Kawabe H, Tsujioka M, Hirose H, Shibata H : Trends in pharmacologic management of hypertension in Japan one year after the publication of the JSH 2000 guidelines. Hypertens Res 2002; 25: 175–178.
Lopez J, Meier J, Cunningham F, Siegel D : Antihypertensive medication use in the Department of Veterans Affairs: a national analysis of prescribing patterns from 2000 to 2002. Am J Hypertens 2004; 17: 1095–1099.
Yakugyo Kenkyukai : Nippon Iyakuhin Johoshu (Japanese Pharmacopoeia). Tokyo, Jiho Inc, 2000.
Yakugyo Kenkyukai : Nippon Iyakuhin Johoshu (Japanese Pharmacopoeia). Tokyo, Jiho Inc, 2004.
Mullins CD, Sikirica M, Seneviratne V, Ahn J, Akhras KS : Comparisons of hypertension-related costs from multinational clinical studies. Pharmacoeconomics 2004; 22: 1001–1014.
Saruta T : Hypertension treatment in Japan. Nikkei Medical 2001; 7: 58–63.
Ministry of Labour and Welfare, Japan : Shindangun Bunrui Tensuhyo (Diagnostic Codes and Rates). Tokyo, Shakaihoken Kenkyujo, 2004 ( in Japanese).
Lerner DJ, Kannel WB : Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111: 383–390.
Cigarette smoking as a risk factor in stroke. JAMA 1988; 260: 34.
Kubo M, Kiyohara Y, Kato I, et al: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003; 34: 2349–2354.
Neal B, MacMahon S, Chapman N : Effects of ACE inhibitors, calcium antagonists, and other blood-pressure–lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955–1964.
Turnbull F : Effects of different blood-pressure–lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–1535.
American Diabetes Association : Standards of medical care in diabetes. Diabetes Care 2005; 28: S4–S36.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sakamaki, Y., Sasamura, H., Ikeda, S. et al. Comparison of Health Costs Associated with Treatment of Hypertension with a Calcium Channel Blocker and Angiotensin-Converting Enzyme Inhibitor in the United States and Japan. Hypertens Res 29, 333–338 (2006). https://doi.org/10.1291/hypres.29.333
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.29.333